Cargando…

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fugger, Gernot, Bartova, Lucie, Fabbri, Chiara, Fanelli, Giuseppe, Dold, Markus, Swoboda, Marleen Margret Mignon, Kautzky, Alexander, Zohar, Joseph, Souery, Daniel, Mendlewicz, Julien, Montgomery, Stuart, Rujescu, Dan, Serretti, Alessandro, Kasper, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095529/
https://www.ncbi.nlm.nih.gov/pubmed/34989830
http://dx.doi.org/10.1007/s00406-021-01368-3
_version_ 1784705773340721152
author Fugger, Gernot
Bartova, Lucie
Fabbri, Chiara
Fanelli, Giuseppe
Dold, Markus
Swoboda, Marleen Margret Mignon
Kautzky, Alexander
Zohar, Joseph
Souery, Daniel
Mendlewicz, Julien
Montgomery, Stuart
Rujescu, Dan
Serretti, Alessandro
Kasper, Siegfried
author_facet Fugger, Gernot
Bartova, Lucie
Fabbri, Chiara
Fanelli, Giuseppe
Dold, Markus
Swoboda, Marleen Margret Mignon
Kautzky, Alexander
Zohar, Joseph
Souery, Daniel
Mendlewicz, Julien
Montgomery, Stuart
Rujescu, Dan
Serretti, Alessandro
Kasper, Siegfried
author_sort Fugger, Gernot
collection PubMed
description INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. METHODS: These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. RESULTS: SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. CONCLUSION: A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists’ treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions.
format Online
Article
Text
id pubmed-9095529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-90955292022-05-13 The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries Fugger, Gernot Bartova, Lucie Fabbri, Chiara Fanelli, Giuseppe Dold, Markus Swoboda, Marleen Margret Mignon Kautzky, Alexander Zohar, Joseph Souery, Daniel Mendlewicz, Julien Montgomery, Stuart Rujescu, Dan Serretti, Alessandro Kasper, Siegfried Eur Arch Psychiatry Clin Neurosci Original Paper INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. METHODS: These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. RESULTS: SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. CONCLUSION: A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists’ treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions. Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9095529/ /pubmed/34989830 http://dx.doi.org/10.1007/s00406-021-01368-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Fugger, Gernot
Bartova, Lucie
Fabbri, Chiara
Fanelli, Giuseppe
Dold, Markus
Swoboda, Marleen Margret Mignon
Kautzky, Alexander
Zohar, Joseph
Souery, Daniel
Mendlewicz, Julien
Montgomery, Stuart
Rujescu, Dan
Serretti, Alessandro
Kasper, Siegfried
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title_full The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title_fullStr The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title_full_unstemmed The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title_short The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
title_sort sociodemographic and clinical profile of patients with major depressive disorder receiving ssris as first-line antidepressant treatment in european countries
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095529/
https://www.ncbi.nlm.nih.gov/pubmed/34989830
http://dx.doi.org/10.1007/s00406-021-01368-3
work_keys_str_mv AT fuggergernot thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT bartovalucie thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT fabbrichiara thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT fanelligiuseppe thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT doldmarkus thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT swobodamarleenmargretmignon thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT kautzkyalexander thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT zoharjoseph thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT souerydaniel thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT mendlewiczjulien thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT montgomerystuart thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT rujescudan thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT serrettialessandro thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT kaspersiegfried thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT fuggergernot sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT bartovalucie sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT fabbrichiara sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT fanelligiuseppe sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT doldmarkus sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT swobodamarleenmargretmignon sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT kautzkyalexander sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT zoharjoseph sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT souerydaniel sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT mendlewiczjulien sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT montgomerystuart sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT rujescudan sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT serrettialessandro sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries
AT kaspersiegfried sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries